# Theolytics

Source: https://onco.cc/companies/theolytics/  
OnCo record `theolytics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Theolytics is an Oxford biotech that screens huge libraries of adenoviruses to find ones that kill particular cancers; THEO-260 is its lead for ovarian cancer.

## Summary

Theolytics, spun out of the University of Oxford, uses directed evolution and high-throughput screening of adenovirus libraries to select oncolytic viruses with the best tumour selectivity and potency for a chosen cancer. THEO-260, selected against ovarian cancer cells, entered a phase 1/2 trial in platinum-resistant ovarian cancer in 2024 and is also being developed for intravenous delivery.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Theolytics Ltd
- Tags: drug-maker
- HQ: Oxford
- Type: biotech
- Website: https://www.theolytics.com/

## Sources

- Official website: https://www.theolytics.com/

## Connected records

- drugs: [THEO-260](https://onco.cc/drugs/theo-260/)

---
JSON: https://onco.cc/api/v1/entities/theolytics.json